NewKerala.com

India's Pharma Revolution: How Innovation Will Transform Global Healthcare in 5 Years

India's pharmaceutical sector is undergoing a major transformation from generics to innovation-driven growth. Government reforms and significant R&D investments are accelerating this shift toward advanced therapies. Industry leaders emphasize the need for cross-domain insights and value-driven innovation. The country aims to become a global pharma powerhouse within the next five years through these strategic changes.

Key Points: India Set to Become Innovation-Led Pharma Giant in 5 Years

  • Government reforms include streamlined approvals and Rs 5,000 crore R&D project funding
  • Shift from generics to biosimilars and complex drug development underway
  • New hospital finance scheme of Rs 1 lakh crore strengthens research infrastructure
  • Focus on peptides, biologics and cell therapies for global health impact
2 min read

India well-positioned to become innovation-led pharma giant in next 5 years: CDSCO

CDSCO official reveals India's shift from generics to innovation with Rs 5,000 crore R&D push, biosimilars, and regulatory reforms positioning as global pharma leader.

"India is well positioned to evolve from being the pharmacy of the world to an innovation-led pharma nation - Dr. R Chandrashekar, CDSCO"

New Delhi, Nov 26

India is well positioned to evolve from being the pharmacy of the world to an innovation-led pharma nation over the next five years, said Dr. R Chandrashekar, Joint Drugs Controller, the Central Drugs Standard Control Organization (CDSCO).

He was speaking at the three-day 18th CPHI & PMEC India, being held in Greater Noida, from November 25 to November 27.

“The government and CDSCO reforms, such as streamlined approvals, reduced regulatory layers, decriminalisation of non-serious offences, and the recommendation of R&D projects worth Rs 5,000 crore. The newly launched hospital finance scheme of Rs 1,00,000 crore further strengthens the country’s R&D landscape,” Chandrashekar said, while addressing the media.

“India’s pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem, with growing emphasis on biosimilars, peptides, complex generics and next-generation biologics,” he added.

Namit Joshi, Chairman, Pharmaceuticals Export Promotion Council of India (Pharmexcil), urged the need for India to evolve beyond its traditional generics mindset and adopt "cross-domain insights, and a more innovation-led approach to strengthen India’s role in shaping the next era of global healthcare".

“The future lies in value-driven innovation, advancing capabilities in peptides, complex generics, biosimilars, biologics, targeted drug delivery systems, and cell and gene therapies. Breakthrough classes such as GLP-1 inhibitors are redefining global health outcomes, and Indian manufacturers are already preparing to enter these high-value segments as patents expire,” Joshi added.

Anil Matai, Director General, Organization of Pharmaceutical Producers of India (OPPI), said that while India has firmly established itself as the ‘Pharmacy to the World,’ it is now transitioning toward becoming a true pharma powerhouse.

“This shift is supported by enabling regulations, improved processes, and a growing emphasis on innovation, stronger intellectual property protection, and the elimination of patent infringements. These reforms reflect the government’s broader vision to ‘discover in India, innovate in India and innovate for the world,’ and the first steps toward that future are already visible,” Matai added.

- IANS

Share this article:

Reader Comments

R
Rohit P
About time! Our scientists and researchers are world-class but we've been stuck in generics. The shift to biosimilars and complex generics will put us on global innovation map. Great to see regulatory reforms too.
A
Arjun K
While this sounds promising, I hope the focus remains on making medicines affordable for common Indians. Innovation shouldn't mean unaffordable healthcare. Let's balance global ambitions with domestic needs.
S
Sarah B
As someone working in pharma R&D, this is exactly what we needed! The regulatory streamlining and Rs 1,00,000 crore hospital finance scheme will accelerate our research. Exciting times ahead for Indian pharma! 🎯
V
Vikram M
Cell and gene therapies, GLP-1 inhibitors - these are the future! Glad Indian companies are preparing for patent expiries. We need more private investment in R&D though, can't rely only on government schemes.
M
Michael C
The 'discover in India, innovate for the world' vision is ambitious but achievable. Stronger IP protection is crucial to attract global partnerships. Hope we see concrete results in the next 2-3 years.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50